Andrew Bryant, M.D. | American Lung Association

Location Select your location

Andrew Bryant, M.D.

University of Florida
Targeting Protein May Reduce Severity of Pulmonary Hypertension

High blood pressure in the lungs, known as pulmonary hypertension , complicates the care of many patients with chronic lung disease, such as idiopathic pulmonary fibrosis. This results in frequent hospitalization and an increased risk of death. While it is known that myeloid-derived suppressor cells (M.D.SCs), a population of cells connected with malignant tumor growth and spread, are associated with the development of pulmonary hypertension, the way in which these cells are recruited to the lung is unknown. We will use animal models to investigate the hypothesis that deleting a protein called chemokine receptor CXCR2 can reduce the severity of pulmonary hypertension. The project could lead to identification of a novel target for l treatment.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.